Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.110122 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.110122 32759007!7373045!32759007     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2020 ; 143 (ä): 110122 Nephropedia Template TP {{tp|p=32759007|t=2020. Prostaglandin D(2) as a mediator of lymphopenia and a therapeutic target in COVID-19 disease |pdf=|usr=}}{{32759007}} gab.com Text Prostaglandin D(2) as a mediator of lymphopenia and a therapeutic target in COVID-19 disease JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32759007 #FOAvip A characteristic feature of COVID-19 disease is lymphopenia. Lymphopenia occurs early in the clinical course and is a predictor of disease severity and outcomes. The mechanism of lymphopenia in COVID-19 is uncertain. It has been variously attributed to the release of inflammatory cytokines including IL-6 and TNF-alpha; direct infection of the lymphocytes by the virus; and rapid sequestration of lymphocytes in the tissues. Additionally, we postulate that prostaglandin D(2) (PGD(2)) is a key meditator of lymphopenia in COVID-19. First, SARS-CoV infection is known to stimulate the production of PGD(2) in the airways, which inhibits the host dendritic cell response via the DP(1) receptor signaling. Second, PGD(2) is known to upregulate monocytic myeloid-derived suppressor cells (MDSC) via the DP(2) receptor signaling in group 2 innate lymphoid cells (ILC2). We propose targeting PGD(2)/DP(2) signaling using a receptor antagonist such as ramatroban as an immunotherapy for immune dysfunction and lymphopenia in COVID-19 disease. Twit Text FOAVip Prostaglandin D(2) as a mediator of lymphopenia and a therapeutic target in COVID-19 disease ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32759007 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32759007 #FOAvip English Wikipedia <ref>{{Cite pmid|32759007}}</ref> Prostaglandin D(2) as a mediator of lymphopenia and a therapeutic target in COVID-19 disease #MMPMID32759007 Gupta A; Chander Chiang K Med Hypotheses 2020[Oct]; 143 (ä): 110122 PMID32759007show ga A characteristic feature of COVID-19 disease is lymphopenia. Lymphopenia occurs early in the clinical course and is a predictor of disease severity and outcomes. The mechanism of lymphopenia in COVID-19 is uncertain. It has been variously attributed to the release of inflammatory cytokines including IL-6 and TNF-alpha; direct infection of the lymphocytes by the virus; and rapid sequestration of lymphocytes in the tissues. Additionally, we postulate that prostaglandin D(2) (PGD(2)) is a key meditator of lymphopenia in COVID-19. First, SARS-CoV infection is known to stimulate the production of PGD(2) in the airways, which inhibits the host dendritic cell response via the DP(1) receptor signaling. Second, PGD(2) is known to upregulate monocytic myeloid-derived suppressor cells (MDSC) via the DP(2) receptor signaling in group 2 innate lymphoid cells (ILC2). We propose targeting PGD(2)/DP(2) signaling using a receptor antagonist such as ramatroban as an immunotherapy for immune dysfunction and lymphopenia in COVID-19 disease. |*Betacoronavirus[MESH] |*Models, Immunological[MESH] |*Molecular Targeted Therapy[MESH] |*Pandemics[MESH] |Adult[MESH] |COVID-19[MESH] |Carbazoles/pharmacology/therapeutic use[MESH] |Child[MESH] |Coronavirus Infections/complications/immunology/*physiopathology[MESH] |Dendritic Cells/immunology[MESH] |Humans[MESH] |Lymphopenia/etiology/*physiopathology[MESH] |Myeloid Cells/immunology[MESH] |Pneumonia, Viral/complications/immunology/*physiopathology[MESH] |Prostaglandin D2/biosynthesis/*physiology[MESH] |Receptors, Immunologic/antagonists & inhibitors/metabolism[MESH] |Receptors, Prostaglandin/antagonists & inhibitors/metabolism/physiology[MESH] |Respiratory System/*metabolism[MESH] |SARS-CoV-2[MESH] |Sulfonamides/pharmacology/therapeutic use[MESH] |T-Lymphocytes/immunology[MESH]Prostaglandin D(2) as a mediator of lymphopenia and a therapeutic targ(epmc).pdf DeepDyve Pubget Overpricing